NeuroBo And MThera Team Up For Diabetic Neuropathy Treatment

NeuroBo Pharmaceuticals, Inc., a biotechnology firm in the clinical stage dedicated to addressing cardiometabolic disorders, has officially entered into an exclusive licensing deal with MThera Pharma Co., Ltd. (MTHERA). This agreement grants MTHERA the rights to develop NB-01 for managing painful diabetic neuropathy. Under this partnership, MTHERA is authorized to pursue research and clinical studies, which may include a prospective Phase 3 trial in both the United States and South Korea, aimed at bringing NB-01 to market. The financial details of the agreement have not been made public.

Hyung Heon Kim, President and Chief Executive Officer of NeuroBo, “Finalizing this agreement for NB-01 is an important milestone for NeuroBo, reflecting our stated commitment to out-license our legacy assets in order to focus on the continued clinical development of DA-1726 and DA-1241. MTHERA has extensive experience in manufacturing, quality control and clinical development of natural medicines and botanical drugs, making the company an ideal partner to continue the development of NB-01."

"Based on the positive Phase 2 efficacy results for NB-01 for diabetic neuropathy, we intend to develop it as a potential treatment for peripheral diabetes. Utilizing our SyMthomics platform technology, we can clearly identify the mechanism of action and active ingredients of NB-01 to assist in predicting its clinical efficacy as an innovative treatment, with the intent of advancing NB-01 into the next phase of clinical development. We are grateful to NeuroBo for the opportunity to further advance NB-01, and to potentially bring this promising therapy to patients in need,” added Dr. Mi Won Sohn, Chief Executive Officer of MTHERA.